A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

Clinical trial NCT07562581 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07562581
Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Caner KRAS-mutated Metastasis Previous Treamted

Start date: 2026-06-01
Primary completion: 2029-06-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.